The introduction of EGFR tyrosine kinase inhibitors (TKIs) has transformed the therapeutic approach for advanced NSCLC patients with EGFR mutations, establishing them as the primary treatment option and significantly enhancing survival (Rosell et al., 2012). Here, EGFR is linked to non-small cell lung carcinoma.